{
    "root": "a8d088b3-fe77-498a-bfe9-6274d1fda17f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ESZOPICLONE",
    "value": "20250502",
    "ingredients": [
        {
            "name": "ESZOPICLONE",
            "code": "UZX80K71OE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53760"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": {
        "text": "eszopiclone tablets indicated treatment insomnia . controlled outpatient sleep laboratory , eszopiclone tablets administered bedtime decreased sleep latency improved sleep maintenance . trials performed support efficacy 6 months duration . final formal assessments sleep latency maintenance performed 4 weeks 6-week study ( adults ) , end 2-week ( elderly ) end 6-month study ( adults ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest effective dose patient .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "eszopiclone tablets usp 1 mg light blue colored , film-coated , round shaped , biconvex tablets debossed \u2018 k \u2019 one side \u2018 83 \u2019 side . bottles 7 ndc 68788-7667-07bottles 10 ndc 68788-7667-01bottles 15 ndc 68788-7667-05bottles 20 ndc 68788-7667-02bottles 30 ndc 68788-7667-03bottles 60 ndc 68788-7667-06bottles 90 ndc 68788-7667-09bottles 100 ndc 68788-7667-00 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022eszopiclone tablets contraindicated patients experienced complex sleep behaviors taking eszopiclone tablets [ ( 5.1 ) ] . \u2022eszopiclone tablets contraindicated patients known hypersensitivity eszopiclone . hypersensitivity include anaphylaxis angioedema [ ( 5.3 ) ] .",
    "indications_original": "Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. \n                  The clinical trials performed in support of efficacy were up to 6 months in duration.\u00a0 The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).",
    "contraindications_original": "Use the lowest effective dose for the patient.",
    "warningsAndPrecautions_original": "Eszopiclone Tablets USP 1 mg are light blue colored, film-coated, round shaped, biconvex tablets with debossed \u2018K\u2019 on one side and \u201883\u2019 on other side.\n                        Bottles of 7\tNDC 68788-7667-07Bottles of 10\tNDC 68788-7667-01Bottles of 15\tNDC 68788-7667-05Bottles of 20\tNDC 68788-7667-02Bottles of 30\tNDC 68788-7667-03Bottles of 60\tNDC 68788-7667-06Bottles of 90\tNDC 68788-7667-09Bottles of 100\tNDC 68788-7667-00\n                     \n                        \u00a0\n                        Store at \t20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022Eszopiclone tablets are contraindicated in patients who have experienced complex sleep behaviors after taking Eszopiclone tablets [see Warnings and Precautions (5.1)]. \n                     \n                     \n                        \u2022Eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema [see Warnings and Precautions (5.3)].",
    "drug": [
        {
            "name": "ESZOPICLONE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53760"
        }
    ]
}